4Q Revenues: $5.0 million (-23%)
4Q Loss: $721,000 (loss of $404,000 4Q14)
FY Revenues: $22.7 million (-8%)
FY Earnings: $1.1 million (loss of $1.1 million FY14)
Comments: Service revenue for the quarter decreased 22% to $3.8 million, negatively impacted by fewer bioequivalence studies, as well as fewer samples received and analyzed. Product revenue was $1.1 million, down 25% impacted by lower sales of analytical instruments relating to Culex.